Perfil de la empresa · Healthcare

Boston Scientific Corp

BSX · EE. UU.
Bolsa
EE. UU.
País / Región
USA
Fecha de salida a bolsa
18 de mayo de 1992
Empleados
59.000
Precio actual
$45.29
En vivo · 18 de junio de 2026
Puntuación de crecimiento Baillie
46/100
Floja
Valor intrínseco · Rango en tres niveles Precio actual $45.29 En vivo · Entre el rango conservador y el razonable

Rango de valoración compuesto · conservador $31–$40 / razonable $50–$65 / optimista $80–$95. A $45.29, Entre el rango conservador y el razonable.

Al publicar $57.78 (24 de mayo de 2026)

Aún no hay análisis sobre este valor en tu idioma.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Capitalización66,81 mil MUS$
Ingresos (TTM)20,61 mil MUS$
EBITDA5500 MUS$
Margen neto17,29 %
ROE14,66 %
PER (TTM)18,81
PER previsto13,39
PEG0,54
BPA2,39 US$
Rango de 52 semanas44,80 US$ – 109,50 US$
Precio objetivo de analistas77,10 US$
Recomendación de analistas4.6 / 5

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

Historia

PróximamenteEsta sección se está completando; vuelve pronto.

Posición en el sector

PróximamenteEsta sección se está completando; vuelve pronto.